Form 4: Tempest Therapeutics Director Michael Raab Acquires Stock Options

Director Michael Raab acquired stock options in Tempest Therapeutics, Inc. on June 13, 2024.

Summary

• Michael Raab, a director of Tempest Therapeutics, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction on June 13, 2024, where Raab acquired stock options to purchase 16,000 shares of Tempest Therapeutics common stock at an exercise price of $3.03.
• The options vest fully on the earlier of June 13, 2025, or the date of the Issuer's 2025 annual stockholder meeting, contingent upon continuous service.
• Following the transaction, Raab directly owns 16,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither overwhelmingly positive nor negative on its own. The director's acquisition suggests confidence, but it's a routine part of compensation.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the options is contingent on continuous service, suggesting an expectation of continued involvement by the director.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of the options, contingent on continued service, aligns with typical industry practices to incentivize long-term commitment.
• Comparing the exercise price and the number of options granted to similar companies and executive roles would provide a more detailed assessment of the grant's competitiveness.

Stakeholder Impact

• The acquisition of stock options by a director can have a minor positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates